Ensysce Biosciences Receives Investigational New Drug Allowance for its Unique PF614-MPAR™ Opioid with Overdose Protection
Retrieved on:
Thursday, April 29, 2021
The MPAR\xe2\x84\xa2 overdose protection technology has been demonstrated in animals and the Phase 1 study with PF614 is being conducted to further validate the MPAR\xe2\x84\xa2 overdose protection technology.
Key Points:
- The MPAR\xe2\x84\xa2 overdose protection technology has been demonstrated in animals and the Phase 1 study with PF614 is being conducted to further validate the MPAR\xe2\x84\xa2 overdose protection technology.
- \xe2\x80\x9cImportantly, our proprietary prodrug approach is highly differentiated from currently marketed opioid products and designed to significantly reduce abuse potential and overdose protection.
- The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug prodrug compositions.
- Additional information can be found at www.leisureacq.com .\nThis press release relates to a proposed transaction between Ensysce and LACQ.